Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

In patients without disease progression following first-line chemotherapy (n=700), the addition of maintenance avelumab to best supportive care was associated with prolonged overall survival (median 21.4 vs. 14.3 months; HR 0.69; 95% CI 0.56 to 0.86; P=0.001).


New England Journal of Medicine